Gozzetti Alessandro, Tozzuoli Daniela, Crupi Rosaria, Fanelli Albertina, Gentili Sara, Bocchia Monica, Mazzotta Serena, Raspadori Donatella, Lauria Francesco
Division of Hematology and Transplants, Department of Medicine and Immunological Sciences, University of Siena, Policlinico Le Scotte, 53100 Siena, Italy.
Cancer Genet Cytogenet. 2004 Jan 15;148(2):152-4. doi: 10.1016/s0165-4608(03)00260-7.
Emergence of additional cytogenetic clones in chronic myelocytic leukemia (CML) patients who become Philadelphia chromosome-negative (Ph-) after alpha-interferon therapy (or more recently with imatinib mesylate) have been described. We report here a case of a novel t(6;7)(p21;q23) that developed in a CML patient in complete cytogenetic remission during imatinib therapy. In this case, fluorescence in situ hybridization and reverse transcriptase polymerase chain reaction showed a normal pattern for BCR and ABL genes, suggesting that a different and unrelated clone developed after the disappearance of the Ph chromosome.
已有报道称，慢性粒细胞白血病（CML）患者在接受α干扰素治疗（或最近使用甲磺酸伊马替尼）后变为费城染色体阴性（Ph-），会出现额外的细胞遗传学克隆。我们在此报告一例新型t(6;7)(p21;q23)，该克隆在一名CML患者接受伊马替尼治疗期间处于完全细胞遗传学缓解时出现。在这个病例中，荧光原位杂交和逆转录聚合酶链反应显示BCR和ABL基因呈正常模式，这表明在Ph染色体消失后出现了一个不同且不相关的克隆。
